相关实验视频

Updated: Jun 26, 2025

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

在预透析中验证了SGLT2i的实时使用:RSVP横截面研究

Aylon Wisbaum¹, Sandrine Gaudreau², Isabelle Cloutier³

¹Santé Mont Royal Medical Center, Montreal, QC, Canada.

The Annals of pharmacotherapy

|May 13, 2024

概括

-葡萄糖共运输体2抑制剂 (SGLT2i) 越来越多地用于科. 然而,慢性病 (CKD) 患者处方模式的差异仍然存在,需要有针对性的策略来确保公平的护理.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
药理学药理学是指药理学的学科.
内部医学内部医学

背景情况:

-葡萄糖共运输体2抑制剂 (SGLT2i) 是糖尿病或蛋白尿症患者的日益增长的护理标准.
它们在病学中的作用正在扩大,促使对当前的处方实践进行调查.

研究的目的:

确定患有慢性病 (CKD) G3a,G3b或G4阶段的预透析患者中,被处方SGLT2i的比例.
描述这些患者的特征,并确定与SGLT2i处方相关的因素.

主要方法:

这是一项回顾性,多中心,横截面研究,涉及加拿大北克4家诊所的874名透析前患者.
在18岁以上的CKD G3a-G4.4患者中,收集了与SGLT2i处方相关的共变量数据.
进行多变量逻辑回归分析以确定有意义的关联.

主要成果:

22.7%的符合条件的CKD患者被处方SGLT2i.
与SGLT2i处方显著相关的因素包括男性性别,甲胺使用,2型糖尿病和高专与肌素比率 (>300 mg/g).
大多数SGLT2i处方 (60.4%) 是由透析前诊所发起的;最常见的不良事件是血清肌素的短暂增加.

结论:

在CKD患者中,SGLT2i的处方正在增加,但存在与性别,疾病严重程度和并发症相关的显著差异.
建议制定有针对性的战略,以促进SGLT2i在代表性不足的群体中使用,特别是妇女和其他处于风险人群中使用.
在科团队中加强公平的处方实践对于改善患者护理和结果至关重要.

关键词:

-葡萄糖共运输体2抑制剂慢性脏疾病慢性脏疾病实践的差距实践的差距透析前的治疗方法处方模式的规定模式.

更多相关视频

Transcutaneous Assessment of Renal Function in Conscious Rodents

Transcutaneous Assessment of Renal Function in Conscious Rodents

Published on: March 26, 2016

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Secondary Active Transport

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...